A study suggests that sequencing TP53 and MYOD1 can improve risk stratification for patients with rhabdomyosarcomas. It suggests that sequencing should be completed for each patient to determine which treatment regimen will most likely be effective.

©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.